MTOR and idiopathic pulmonary fibrosis: The potential application of mTOR inhibitors for pulmonary fibrosis was discouraged by a clinical study that showed everolimus, another mTOR inhibitor other than rapamycin, was associated with more rapid disease progression in patients with surgical lung biopsy-confirmed IPF[37].